At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 849 enrolled
Drug / intervention
tanezumab 10 mg +3 morebiological
Likely dose
tanezumab 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO AND NAPROXEN CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE
In Brief
A Phase 3 clinical trial evaluating tanezumab 10 mg, tanezumab 5 mg, and 2 other interventions for Osteoarthritis. Completed, enrolled 849 participants across 95 sites.
Detailed Summary
Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2009
Enrollment StartJun 2009
Primary CompletionApr 2010
Study CompletionAug 2010
TodayJul 2026
First PostedMar 17, 2009
Enrollment StartJun 9, 2009
Primary CompletionApr 27, 2010
Study CompletionAug 16, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.3 years ago
Interventions
tanezumab 10 mgbiological
tanezumab 10 mg one dose at weeks 0 and 8
tanezumab 5 mgbiological
tanezumab 5 mg one dose at weeks 0 and 8
naproxendrug
naproxen 1000 mg daily for 16 weeks
placeboother
placebo to match tanezumab and naproxen dosing